Search Within

Igor Odintsov

  1. "Elsevier Inc."
Formats
  1. Journal Article (3)
  2. Meeting Abstract (1)
Groups
  1. Department of Pathology and Laboratory Medicine (4)
  2. GSK Faculty (4)
  3. Human Oncology and Pathogenesis Program (4)
  4. Sloan Kettering Institute Postdocs (4)
  5. Tow Center for Developmental Oncology (TCDO) (4)
  6. Department of Medicine (2)

More Groups

People
  1. Marc Ladanyi (4)
  2. Romel Somwar (4)
  3. Elisa De Stanchina (3)
  4. Inna Khodos (2)
  5. Jo Weng Allan Lui (2)
  6. Lukas Delasos (2)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2021 (1)
  4. 2020 (1)
Publications
  1. Journal of Thoracic Oncology (3)
  2. European Journal of Cancer (1)
Publishers
  1. Elsevier Inc. (4)

Results (4)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HER4 and EGFR activate cell signaling in NRG1 fusion-driven cancers: Implications for HER2-HER3-specific versus pan-HER targeting strategies
    Journal Article

    Udagawa, H.; Nilsson, M. B.; Robichaux, J. P.; He, J.; Poteete, A.; Jiang, H.; Heeke, S.; Elamin, Y. Y.; Shibata, Y.; Matsumoto, S.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Combination therapy with MDM2 and MEK inhibitors is effective in patient-derived models of lung adenocarcinoma with concurrent oncogenic drivers and MDM2 amplification
    Journal Article

    Elkrief, A.; Odintsov, I.; Markov, V.; Caeser, R.; Sobczuk, P.; Tischfield, S. E.; Bhanot, U.; Vanderbilt, C. M.; Cheng, E. H.; Drilon, A.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers
    Journal Article

    Odintsov, I.; Mattar, M. S.; Lui, A. J. W.; Offin, M.; Kurzatkowski, C.; Delasos, L.; Khodos, I.; Asher, M.; Daly, R. M.; Rekhtman, N.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements
    Meeting Abstract

    Odintsov, I.; Gladstone, E.; Sisso, W. J.; Delasos, L.; Lui, A. J. W.; Sisso, E. M.; Vojnic, M.; Khodos, I.; Mattar, M. S.; de Stanchina, E.; more...
    European Journal of Cancer (2020)

    Fulltext@MSK | Save